Atavistik Bio, a US-based biotechnology company discovering the next generation of precision allosteric therapeutics, has announced the appointment of Dr. Susan Pandya as Chief Medical Officer (CMO). 

Dr. Pandya brings 20 years of drug development expertise in precision medicine in both oncology and hematology, with previous senior leadership roles at Servier Pharmaceuticals and Agios Pharmaceuticals.

As CMO, Dr. Pandya will lead all clinical development strategy and execution for Atavistik Bio, including the ongoing Phase 1 clinical trial of its lead programme, ATV-1601, an allosteric selective inhibitor for AKT1 E17K-driven solid tumours. She will also play a central role in advancing the company’s preclinical pipeline into efficient and well-designed clinical trials.    

Bryan Stuart, CEO at Atavistik Bio, commented, “We are very excited to welcome Susan to the Atavistik Bio team as we transition to a clinical stage organisation. Susan’s expertise in guiding oncology programmes through early development, global registration studies, and marketing approval will be instrumental as we progress the ongoing clinical study of our lead precision allosteric candidate, ATV-1601, while continuing to rapidly advance our other pipeline programs toward the clinic.

Dr. Pandya most recently served as Vice President, Clinical Development and Global Head of late-stage oncology at Servier Pharmaceuticals, where she led all late-stage clinical programmes in oncology and haematology, while also contributing to business development and portfolio strategy. Prior to Servier, she led the clinical development of the isocitrate dehydrogenase (IDH) inhibitor portfolio at Agios Pharmaceuticals, which was acquired by Servier in 2021, and oversaw multiple global drug approvals across a range of oncology indications. Earlier in her career, she focused on early-phase development at Acceleron Pharma.

Dr. Pandya earned her M.D. from Tufts University School of Medicine and completed her residency in internal medicine and fellowship in haematology/oncology before holding a clinical practice at Beth Israel Deaconess Medical Center. She currently serves on the Board of Directors of MOMA Therapeutics.

“Atavistik Bio’s commitment to discovering and developing both best-in-class and first-in-class allosteric therapeutics for significantly underserved patient populations represents an important advancement in the field of precision oncology medicine,” Dr. Pandya said.

“I am thrilled to join this exceptional team at such a pivotal time for the company, and I look forward to helping advance this exciting portfolio of novel precision allosteric therapeutics for patients in dire need of new therapeutic options,” she added.